All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub.
What were your highlights from ASH 2023?
Bar-Natan discusses recent data on menin inhibitors for the treatment of relapsed/refractory KMT2A-rearranged or NPM1-mutated acute myeloid leukemia. This includes trials assessing JNJ-75276617 monotherapy, revumenib monotherapy (AUGMENT-101 trial), revumenib in combination with decitabine and cedazuridine plus venetoclax, and ziftomenib in combination with either intensive chemotherapy or non-intensive chemotherapy in both relapsed/refractory and first-line settings.
This interview is also available as a podcast here.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox